Reuters -- Sun Pharmaceutical Industries will stop selling generic version of Sanofi-Aventis’ cancer drug Eloxatin in the United States after June 30 following a court order, the Indian drugmaker said.
Reuters -- Sun Pharmaceutical Industries will stop selling generic version of Sanofi-Aventis’ cancer drug Eloxatin in the United States after June 30 following a court order, the Indian drugmaker said.